Versamune HPV plus pembrolizumab showed a median OS of 30.0 months in checkpoint inhibitor–naive patients with HPV16-positive recurrent/metastatic HNSCC. #hnscc #oncology onclive.com/view/versamune…

Talquetamab generated responses and was safe in patients with relapsed/refractory multiple myeloma who received prior treatment with T-cell–directed therapies, including in those with other medical conditions or poor functional status. ASCO #ASCO24 #mmsm onclive.com/view/talquetam…

Hypofractionation radiotherapy showed noninferior DFS compared with conventional fractionation in patients with low-risk prostate cancer from the phase 3 RTOG 0415 study. Journal of Clinical Oncology #oncology #pcsm onclive.com/view/hypofract…

Arndt Vogel, MD, discusses the updated OS analysis of CARES-310, as well as future directions for rivoceranib plus camrelizumab in unresectable HCC. Arndt Vogel Princess Margaret Cancer Centre #hcc #oncology onclive.com/view/frontline…

Long-term data from clinical trials presented at the 2023 ASH Annual Meeting added further insight to frontline treatment selections for patients with CLL/SLL. UPMC Hillman Cancer Center #leusm #oncology onclive.com/view/long-term…

In the phase 1 AMPLIFY-7P trial, the adjuvant lymph node–targeted amphiphile vaccine ELI-002 7P was well tolerated and bolstered mKRAS–specific T-cell responses in patients with MRD–positive pancreatic and colorectal cancers. ASCO #ASCO24 #pancsm #crcsm onclive.com/view/amphiphil…

The universal cancer vaccine UV1 added to the PD-1 inhibitor pembrolizumab elicited sustained overall survival OS outcomes as frontline therapy in patients with advanced, unresectable, or metastatic malignant melanoma. onclive.com/view/uv1-cance…

WATCH: Lori Wirth, MD, moderates a panel of medical experts specializing in radioactive iodine-refractory differentiated thyroid cancer, discussing current treatments and ongoing clinical trials in this field. #oncology #hncsm onclive.com/view/different…

Elevate your medical insights! Join MedNewsWeek on June 29th for a deep dive into Improving CAR-T Therapy in Multiple Myeloma with Rahul Banerjee, MD, FACP Rahul Banerjee, MD, FACP 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Yan Leyfman, MD #MedicalSpotlight

Register now: ow.ly/JHn950Sc0B5

ARASENS Trial Demonstrates Significant Survival Benefits With Triplet Therapy in mHSPC Marc-Oliver Grimm @asco #ASCO24 #pcsm
onclive.com/view/arasens-t…

Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer Mansoor Mirza ESMO - Eur. Oncology #ESMOGynae24 #gynsm onclive.com/view/dostarlim…

Financial Milestones Achieved by Innovative Management Services Organization #oncology #medtwitter onclive.com/view/financial…

Don't forget to check out the June issue of OncologyLive® honoring the 2024 Giants of Cancer Care inductees! This month's edition is available for download here: ow.ly/haTM50Sp9qP

First-Line Osimertinib Plus Chemo Approved in Japan for EGFR+ Advanced NSCLC #lcsm #oncology onclive.com/view/first-lin…

First-Line Toripalimab Plus Chemo Wins Approval in China for Advanced TNBC #oncology #bcsm

onclive.com/view/first-lin…

Adjuvant Durvalumab Misses DFS End Point in Resected, PD-L1+ Stage IB-IIIA NSCLC #lcsm #oncology onclive.com/view/adjuvant-…

Perioperative Durvalumab Plus Chemo Meets EFS, OS End Points in MIBC Tom Powles #blcsm #oncology onclive.com/view/periopera…

Linvoseltamab Displays Durable Efficacy in Relapsed/Refractory Multiple Myeloma The James #mmsm onclive.com/view/linvoselt…

Addressing the Logistics of At-Home Cancer Care With Subcutaneous Administration of Immunotherapy
Jorge Nieva USC Norris COE Keck Medicine of USC #oncology #lcsm #MedTwitter
onclive.com/view/addressin…

Lurbinectedin and irinotecan combination produced a 43.6% overall response rate in high-risk patients with SCLC. Luis Paz-Ares Complutense ASCO #ASCO24 #lcsm onclive.com/view/lurbinect…